By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed innovative biologic drug, T-Bren for Injection (HER2 ADC), has completed first-patient enrollment in a randomized, controlled Phase III clinical trial evaluating the agent versus investigator’s choice of chemotherapy in patients with HER2-expressing locally advanced or metastatic biliary tract cancer who failed prior platinum-based chemotherapy.
Clinical Development Milestone
| Item | Detail |
|---|---|
| Company | Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) |
| Drug Candidate | T-Bren (BL-M07D1) for Injection |
| Drug Class | HER2-targeted antibody-drug conjugate (ADC) |
| Trial Phase | Phase III (first patient enrolled) |
| Trial Design | Randomized, controlled |
| Comparator | Investigator’s choice of chemotherapy |
| Patient Population | HER2-expressing locally advanced or metastatic biliary tract cancer patients who failed prior platinum-based chemotherapy |
| Global Trial Portfolio | 19 active clinical trials (8 Phase III, 1 Phase II/III, 4 Phase II, 3 Phase I/II, 3 Phase I) |
Drug Profile & Mechanism of Action
- Molecule: Innovative HER2-targeted antibody-drug conjugate (ADC) with best-in-class potential
- Target: HER2 (human epidermal growth factor receptor 2) expressed on tumor cells
- Innovation: Proprietary linker-payload technology designed to maximize tumor-specific drug delivery while minimizing systemic toxicity
- Clinical Evidence: Demonstrated significant antitumor efficacy across multiple tumor types in earlier-phase trials
- Development Strategy: Broad indication expansion across HER2-expressing solid tumors
Global Clinical Trial Portfolio
T-Bren is currently being evaluated in 19 clinical trials globally and domestically, spanning multiple indications:
- Breast Cancer: First-line and second-line/later HER2-positive, HER2-low, adjuvant and neoadjuvant settings
- Gastrointestinal Cancers: HER2-positive gastric or gastroesophageal junction adenocarcinoma
- Lung Cancer: HER2-mutated non-squamous non-small cell lung cancer
- Biliary Tract Cancer: HER2-positive disease following platinum-based chemotherapy failure
- Other Solid Tumors: Lung, gastrointestinal, urological, and gynecological cancers with HER2 expression
Market Impact & Strategic Outlook
- Biliary Tract Cancer Landscape: Limited treatment options post-platinum failure; estimated 20,000 new cases annually in major markets with ~15-20% HER2 positivity rate
- ADC Market Opportunity: Global ADC market projected to reach $16.4 billion by 2026, with HER2-targeted agents representing the largest segment
- Competitive Positioning: T-Bren represents one of the few HER2 ADCs specifically developed for biliary tract cancer, potentially offering first-mover advantage in this niche indication
- Revenue Potential: Successful Phase III completion could position T-Bren for peak annual sales of $500-700 million across all indications
- Strategic Significance: Validates Sichuan Biokin’s transition from generic manufacturer to innovative biotech company with global ambitions
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for T-Bren. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech